Answers are grounded in this paper and cite their sources.
Inclisiran significantly reduced LDL-C. The dosing schedule promoted high adherence in a real-world setting, particularly among older adults with ASCVD. These findings indicate inclisiran may be a particularly valuable addition to lipid-lowering strategies.
No takes yet. Share an insight, caveat, or question.
Ballantyne et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: